Forest Depression Drug Found to Be Superior
Posted on: Wednesday, 6 December 2006, 21:00 CST
Forest Laboratories has said a new study demonstrates that Lexapro was more effective and better tolerated than the rival drug Cymbalta in major depressive disorder.
At the end of the study, Lexapro patients demonstrated greater improvement than Cymbalta patients as measured by a standard depression rating system known as MADRS (Montgomery and Aasberg Depression Rating Scale). The proportion of patients responding to Lexapro treatment, as determined by a 50% improvement in MADRS total score, was also greater. In the Lexapro group the response was 68% compared to 52% in the Cymbalta group. More patients in the Lexapro group completed the treatment than patients in the Cymbalta group.
Lexapro was approved by the FDA in August 2002 for both the initial and maintenance treatment of major depressive disorder in adults, and in December 2003 for the treatment of generalized anxiety disorder in adults.
Lexapro is a selective serotonin reuptake inhibitor (SSRI) that has been prescribed for more than 14 million adult patients in the US. Forest Laboratories licenses Lexapro from Lundbeck, the Danish pharmaceutical firm.
Source: Datamonitor
Related Articles
- INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder
- BioMedEcon Reports Six Times Higher Psychiatric Medication Costs Among Patients With Obsessive-Compulsive Disorder Compared to Patients With Depression
- BioMedEcon Reports Three Times Higher Healthcare Costs Among Patients With Obsessive-Compulsive Disorder Compared to Patients With Depression
- Oculus Innovative Sciences Completes Patient Treatment and Follow-Up in Its Phase II Clinical Trial in Mildly Infected Diabetic Foot Ulcers
- Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
- Patient Treatment for Bipolar Disorder Varies Depending on Doctor Specialty; Well Designed Clinical Trials May Be The Answer
- Data Suggest Cymbalta(R) Improved Functioning in Patients With Generalized Anxiety Disorder
- For the Clinical Management and Treatment of Psychiatric Disorders Once Diagnosed the New Guide a Clinical Guide to the Diagnosis and Treatment of Mental Disorders May Be of Assistance
- Work Starts on ASH's List of Repairs: Recent Analysis Showed Breakdowns in Patient Treatment
- Updated Interim Aranesp(R) Phase 2 Data Suggest Major Response in Anemic Patients With Myelodysplastic Syndrome (MDS); Patients With Bone Marrow Disorder Also Showed Improvements in Hemoglobin Levels and Fatigue
 |
 |
User Comments (2)
| 2. |
Posted by j p on 12/09/2006, 14:47 The sexual side effects while taking Lexapro ( I took it for 12 months) were unacceptable. I have taken Cymbalata for over two years and have had no negative sexual side effects whatsoever. |
| 1. |
Posted by helena tyree on 12/08/2006, 06:45 how long does depression last, even taking lexapro. no other health prblems |
RSS Feeds